Mark A. Rubin, M.D.

Anatomic Pathology and Clinical Pathology
Default Image

Dr. Mark A. Rubin, Professor of Pathology and Laboratory Medicine, serves as Vice Chairman for Experimental Pathology and Director, Translational Research Laboratory Services. Dr. Mark Rubin received his M.D. from Mount Sinai Medical Center and completed training in anatomic pathology at Georgetown University Medical Center followed by a clinical fellowship in anatomic pathology at Johns Hopkins Hospital. His first academic appointment was Assistant Professor of Pathology at Columbia University College of Physicians and Surgeons, followed by Associate Professor of Pathology with Tenure at the University of Michigan and most recently as Associate Professor of Pathology at Harvard Medical School.

Dr. Mark Rubin is one of the foremost academic anatomic pathologists in the United States. He is widely recognized for his clinical diagnostic expertise in prostate pathology. Most recently, he served as Chief of Urologic Pathology at The Brigham and Womenᅡメs Hospital. He has received the two most prestigious awards granted by professional pathology organizations to young investigators. He was awarded the Arthur Purdy Stout Society of Surgical Pathologists Annual Prize in 2003 and the Young Investigator Award from the United States and Canadian Academy of Pathology in 2004, in each case recognizing him as the most prominent pathologist in the United States under the age of 45.

Dr. Rubin is a practicing genitourinary pathologist. The focus of Dr. Rubinᅡメ's laboratory-based research for the past 10 years has been the development of molecular prostate cancer biomarkers to help distinguish indolent from aggressive disease. In collaboration with Arul Chinnaiyanᅡメ's laboratory at the University of Michigan, they identified a common recurrent gene fusion between the TMPRSS2 and ETS genes in the majority of prostate cancers. His work relies on close collaboration with researchers in the fields of urology, medical oncology, clinical outcomes, and molecular biology. His laboratory uses a variety of techniques including RT-PCR, laser capture microdissection, high-density tissue microarrays, SNP arrays, tiling arrays, and cDNA expression arrays in combination with clinical and pathology parameters to identify significant associations. See http://rubinlab.med.cornell.edu/.

Dr. Mark Rubin received his M.D. from Mount Sinai Medical Center and completed training in anatomic pathology at Georgetown University Medical Center followed by a clinical fellowship in anatomic pathology at Johns Hopkins Hospital. His first academic appointment was Assistant Professor of Pathology at Columbia University College of Physicians and Surgeons, followed by Associate Professor of Pathology with Tenure at the University of Michigan and most recently as Associate Professor of Pathology at Harvard Medical School.

Dr. Mark Rubin is one of the foremost academic anatomic pathologists in the United States. He is widely recognized for his clinical diagnostic expertise in prostate pathology.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [Medicare]
  • AETNA [PPO]
  • Aetna - Weill Cornell [POS]
  • Affinity Health Plan
  • CIGNA
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Plus - Amerigroup
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • United Empire
  • United Health Care
  • United Health Care [Community Plan]
  • United Health Care [Medicare]

Publications

Rubin MA, Chinnaiyan AM. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest. 2006;86(11):1099-102.

Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA, Collins C. Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer. Neoplasia. 2006;8(12):1083-9.

Descazeaud A, Rubin MA, Chemama S, Larre S, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Chopin D, Abbou C, de la Taille A. Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. World J Urol. 2006;6(24):676-80.

Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 2006;66(24):11897-906.

Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1):41-51.

Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007.

Prince ME, Ubell ML, Castro J, Ogawa H, Ogawa T, Narayan A, Paulino A, Cole A, Wolf GT, Rubin MA, Lyons RH, Bradford CR, Carey TE. Tissue-preserving approach to extracting DNA from paraffin-embedded specimens using tissue microarray technology. Head Neck. 2007.

Cannon GW, Mullins C, Lucia MS, Hayward SW, Lin V, Liu BC, Slawin K, Rubin MA, Getzenberg RH. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. J Urol. 2007;177(2):610-4; discussion 614.

Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007.

Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39(3):347-351.

Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta K, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB. Comprehensive Assessment of TMPRSS2 and ETS Family Gene Aberrations in Clinically Localized Prostate Cancer. Mod Pathol. 2007 Mar 2;.

Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris P, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA . Morphological Features of TMPRSS2-ERG Gene Fusion Prostate Cancer. J Pathol 2007 Mar 23;.

Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. Corrigendum: High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Apr;39(4):567.

Honors and Awards

Arthur Purdy Stout Society of Surgical Pathologists Annual Prize in 2003

Young Investigator Award from the United States and Canadian Academy of Pathology in 2004.